Celldex Therapeutics ( NASDAQ:CLDX ) has recently emerged as a frontrunner in this arena, unveiling compelling results from its innovative treatment for chronic hives. The consequential findings have ignited a surge in investor enthusiasm, propelling the biotech stock to its highest point since October 2021. Celldex's ( NASDAQ:CLDX ) breakthrough revolves around...
Key Highlights: Positive Phase 2 Study: Celldex Therapeutics revealed positive outcomes from a Phase 2 study of Barzolvolimab, focusing on patients with moderate to severe chronic spontaneous urticaria (CSU) refractory. Well-Tolerated and Favorable Safety Profile: Barzolvolimab demonstrated general well-tolerance and exhibited a favorable safety profile in the...
Potential cup base developing suggests another leg higher Looking at the weekly there's a lot of support here:
CLDX Buy 12.50 Target 1 13.75 Nice pullback on the weekly chart Nothing to the left Wave 3 up 4 down on D1 Looking for a Wave 5 up Target 1 Wave 3 Highs $13.75 Target 2 would be TZ1 $17.00 HIT THE LIIKE BUTTON
Hey guys, me again. Let us take a look at some signals for Friday. EURUSD – On h1, you can see that the price was in a consolidation, and broke out with a bearish impulse. I’d say the price is either going to test the range’s support and fall down, put a target at 1.1250, or break through, test the support from above and go up until at least the top of the range,...
www.biopharmcatalyst.com online.capitalcube.com Looks undervalued to me atm manage your risk GL HF xoxo snoop
Good time to enter CLDX! (1) rising trendline (2) Zacks Rank #2 = buy (short-term for next 1-3 months) (3) Zacks ABR (5 brokers) = 1.80 (almost strong buy); past brokers' recommendations = 2 holds, 3 buys, 0 strong buy, 0 sell, 0 strong sell (4) Zacks' Average Target Price = $6.63 (more than double current price of $3.03) (5) Risk-Reward ratio = 1:1+ Let me know...
CLDX is making higher highs and higher lows, i'm expecting more upside for this one.